Q-omics provides the consensus-scored CLEC3A profile across patient tissues and cancer cell-line models. CLEC3A expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in LUSC. Among the 18 cancer types available for tumor–normal comparison, CLEC3A is differentially expressed in 10, with the highest sampling consensus in BLCA. Additionally, CLEC3A RNA expression shows 7,992 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight LUSC, BLCA, and TGCT as cancer lineages where CLEC3A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CLEC3A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CLEC3A survival associations across molecular data types. CLEC3A RNA expression shows survival associations in the most cancer types (20), followed by mutation status (3) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CLEC3A RNA expression–survival associations across cancer types. High CLEC3A expression shows unfavorable associations in KIRC, BRCA, SCLC, LIHC and KIRP, but favorable associations in LUSC. The LUSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify LUSC as the clearest survival context for CLEC3A RNA expression.
This table summarizes CLEC3A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for CLEC3A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CLEC3A shows lower tumor expression in BLCA, KIRC, KICH, KIRP and UCEC and higher tumor expression in BRCA. The BLCA box plot shows higher CLEC3A RNA expression in normal versus tumor tissue (log2 FC = −4.137, t-test p < 0.001).
This table shows molecular features associated with CLEC3A in patient tissues and cancer cell lines. In patient samples, CLEC3A shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, CLEC3A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Leukemia.
